Is Cosibelimab effective in treating cutaneous squamous cell carcinoma?

Cosibelimab (Cosibelimab) is an anti-PD-L1 monoclonal antibody designed to treat patients with cutaneous squamous cell carcinoma (cSCC), especially those with locally advanced or metastatic cases who are unable to undergo curative surgery or radiotherapy. In December 2024, Cosibelimab was approved by the US FDA and became a new option for the treatment of this type of cancer. The drug activates the patient's own immune system by blocking the binding of PD-L1 and PD-1 receptors to help identify and attack cancer cells.

Clinical trial data show that Cosibelimab is effective in treating cutaneous squamous cell carcinoma. In a pivotal multicenter clinical study, objective response rates were nearly 47% in patients with metastatic cSCC and 48% in patients with locally advanced disease. In terms of response duration, most patients showed long-term treatment benefits. The response time of metastatic patients has not yet reached the median, and the median response time of locally advanced patients reached 17.7 months, which shows the potential of this drug in prolonging the progression-free survival of patients.

The mechanism of action of Cosibelimab not only relies on blocking PD-L1, but its Fc domain can also mediate antibody-dependent cytotoxicity and enhance the killing effect on tumor cells. This multiple mechanism of action allows Cosibelimab to exhibit a strong effect in activating the immune system to fight cancer, providing new treatment opportunities for patients, especially for patients with limited effectiveness of traditional treatments.

In terms of safety, Cosibelimab is generally well tolerated, with common side effects including fatigue, rash, diarrhea, and thyroid dysfunction. The incidence of immune-related adverse reactions is approximately 23%, most of which are mild to moderate, and serious adverse reactions are rare and controllable. During use, patients should regularly monitor their physical condition under the guidance of a doctor and deal with possible side effects in a timely manner to ensure the safety and effectiveness of treatment.

Reference materials:https://www.drugs.com/